Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

FLC Video Highlights Partnership Resulting in Commercialization of axicabtagene ciloleucel

  • Updated:
Dr. Steven Rosenberg and a colleague in the lab at the NCI Surgery Branch

The Success of Partnerships

Dr. Steven Rosenberg shares the story of the development and commercialization of axicabtagene ciloleucel, a highly personalized CAR T-cell immunotherapy for the treatment of cancer. Watch the video.

A video produced by the Federal Laboratory Consortium (FLC) as part of their Labs in Action series highlights a successful NCI partnership to develop and commercialize axicabtagene ciloleucel, a highly personalized CAR T-cell immunotherapy for the treatment of cancer.

FLC Highlights a Successful NCI Collaboration

Axicabtagene ciloleucel was developed by Steven Rosenberg, M.D., Ph.D. (chief, Surgery Branch, Center for Cancer Research, NCI) and his colleagues. It was approved by the FDA on October 18, 2017, for patients with large-B-cell lymphomas whose cancer has progressed after receiving at least two prior treatment regimens.

The technology was licensed to Kite Pharma, Inc., now a Gilead Company, as part of a broader research agreement for further development and commercialization after promising early-phase clinical trials conducted at NCI. “The technology transfer office has been vital to our ability to move from the laboratory into widespread clinical application,” commented Dr. Rosenberg. The video also features the technology transfer perspective of the TTC technology transfer managers involved.

Watch the video produced by the FLC to learn more about the partnership and development of axicabtagene ciloleucel, distributed by Kite as Yescarta®.

Email